AKT1 and acute lymphoblastic leukemia: We tested both idelalisib and GS-649443 on primary patient samples of several genetic subtypes to determine if PI3Kδ inhibitors can suppress homing of ALL cells mediated by SDF-1α and if they affect p-Akt and proliferation of ALL cells.